BIO FPX 1000 Assessment 6 Patient Case Study Profiles Cancer Causes
- High Quality FPX Sample Assessment
- Step-by-Step Guide to master FPX Assessment
- References (APA Format) for related Assessments
- Connect with Top professors for specific class
- Detailed (FAQs) related to Assessment.
- Express Delivery with in 24 hours.
Assessment Overview:
BIO FPX 1000 Assessment 6: focuses on Oncology and Risk Assessment, specifically regarding breast cancer in women. You are required to analyze the profiles of four patients (Mary, Paula, June, and Nora) to identify their unique risk factors, interpret their statistical risk scores via the Breast Cancer Risk Assessment Tool (Gail Model), and provide evidence-based lifestyle and clinical recommendations.
How to Pass BIO FPX 1000 Assessment 6 Patient Case Study Profiles Cancer Causes
- The “Gail Model” Numbers: Ensure you explicitly state how much a patient’s risk exceeds the national average. For example, note that Paula’s 8.3% risk is nearly quadruple the 2.1% average.
- Understand BRCA1/2: When a patient has an extensive family history (like Paula or Nora), emphasize the importance of Genetic Counseling for the BRCA mutation, which significantly increases the risk of breast and ovarian cancers.
- Distinguish Hormonal Risks: Differentiate between Estrogen-only therapy (which may be protective for some) and combined HRT (which can increase risk). Correctly identify that late menopause (like Mary at age 58) increases lifetime exposure to estrogen.
- Trace the Spread: For Paula, note that her bladder cancer has reached the lymphatic vessels. Explain that this system is the “highway” for cancer cells to move (metastasize) to other organs like the ovaries.
- Identify Reproductive Windows: Highlight that age at first pregnancy (Mary at 20) and age of first period (menarche) are critical because they define the total duration of estrogen exposure.
- Address Comorbidities: For June, connect her high cholesterol and hypertension to the DASH (Dietary Approaches to Stop Hypertension) diet. Explain that general health reduces the body’s inflammatory environment.
- Screening Schedules: Recommend Mammograms starting at age 40 for average-risk women, but suggest earlier or more frequent screening (including MRI) for high-risk patients like Paula.
- Correct Misconceptions: In your clinical reasoning, ensure you balance the benefits of oral contraceptives (protecting against ovarian/uterine cancer) with the slight increase in breast cancer risk.
- Lifestyle as Prevention: For all patients, emphasize weight management, as adipose tissue (fat) produces extra estrogen, further increasing cancer risk post-menopause.
- Cite the Tool: Explicitly mention the National Institute of Health (NIH) Breast Cancer Risk Assessment Tool as the source of your statistical projections.
Sample Assessment:
Patient Profile – Cancer Susceptibility in Women
Mary Mary, a strong 64-time old woman, ended her first partition at the age of 20 and entered the menopause in 58. After menopause, he passed estrogen relief treatment about six times, leading to weight gain. His mother’s uncle was diagnosed with bone cancer at the age of 37, and Mary’s first period was 13.00.
Breast Cancer Risks Associated with Mary:
Based on information, Mary increases the risk of developing bench cancer. According to Kłukasiewicz et al.( 2021), women with a family history of cancer have a doubled liability of developing the complaint. The Bone Cancer Risk Assessment Tool indicates a 3.1 chance of invasive bone cancer in the coming five times and a continuance threat of 12.1, surpassing the U.S. normal of 8.1 for women.
Mary’s Recommendation:
Mary is recommended to continue estrogen relief treatment to reduce the risk of bone cancer (Malanonata et al., 2022). Despite the high threats due to family history, the operation of stress is important. Mary should lead a healthy life to maintain a proper diet, avoid alcohol, stay active and see regular leg cancer every 40 days.
Paula At 71, Paula is battling bladder cancer that has spread to her ovaries and lymphatic vessels. Her family passed bone cancer treatment three times , and her mama succumbed to lung cancer. Two paternal uncles and her motherly grandma also faced cancer.
Breast Cancer Risks Associated with Paula:
Paula’s family history indicates a high bone cancer threat. According to Łukasiewicz et al.( 2021), her estimated threat in the coming five times is 8.3, exceeding the U.S. normal of 2.1. Her continuance threat is 18.2, surpassing the 5.1 normal.
Paula’s Recommendation:
Given Paula’s expansive family history, alert is pivotal. Individual wireworks are recommended, especially with her family’s BRCA1 mutation. Also, chemotherapy for bladder cancer is advised( Mar & Dayyani, 2019).
June June, aged 58, undergoes regular mammograms. Her family history includes her aunt’s bone cancer and her mama ’s brain excrescence. June’s blood pressure and cholesterol situations are high, and she has fragile bones.
Breast Cancer Risks Associated with June:
June’s threat of bone cancer in the coming five times is 2.6, higher than the normal of 1.7. Her continuance threat is 14.6, exceeding the 9.5 U.S. normal( National Institute of Health).
June’s Recommendation:
Due to oral contraceptive history, June should suffer regular mammograms with a 7 increased bone cancer threat( Bardaweel et al., 2019). Controlling hypertension and cholesterol through the gusto eating plan is advised, along with a diet rich in calcium to combat osteoporosis.
Nora Nora, 51, has n’t reached menopause, and her family history includes bone and colon cancer.
Breast Cancer Risks Associated with Nora:
Nora’s estimated threat for bone cancer in the coming five times is 3, exceeding the 1.3 normal. Her continuance threat is 23.8, surpassing the 11 U.S. normal.
Nora’s Recommendation:
Nora should undergo BRCA1 testing due to her family history. life changes, similar to avoiding alcohol and maintaining a healthy diet, are pivotal. Regular examinations and addressing threat factors, including age at first gestation and oral contraceptive use, are essential( Bardaweel et al., 2019; Sahin et al., 2019).
BIO FPX 1000 Assessment 6 Patient Case Study Profiles – Cancer Causes
Manyonda, I., Sinai Talaulikar, V., Pirhadi, R., Ward, J., Banerjee, D., & Onwude, J. (2022). Could perimenopausal estrogen prevent breast cancer? Exploring the differential effects of estrogen-only versus combined Hormone Replacement Therapy. Journal of Clinical Medicine Research, 14(1), 1–7. https://doi.org/10.14740/jocmr4646
Mar, K., & Dayyani, F. (2019). Chemotherapy for bladder cancer. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537121/
National Institute of Health. (n.d.). Breast Cancer Risk Assessment Tool. https://bcrisktool.cancer.gov/
Sahin, I., Bilir, B., Ali, S., Sahin, K., & Kucuk, O. (2019). Soy isoflavones in integrative oncology: Increased efficacy and decreased toxicity of cancer therapy. Integrative Cancer Therapies, 18, 153473541983531. https://doi.org/10.1177/1534735419835310
References (APA 7 Format)
- Aurin, J., Thorlacius, H., & Butt, S. T. (2020). Age at first childbirth and breast cancer survival: a prospective cohort study. BMC Research Notes, 13(1). https://doi.org/10.1186/s13104-019-4864-1
- Bardaweel, S. K., Akour, A. A., Al-Muhaissen, S., AlSalamat, H. A., & Ammar, K. (2019). Oral contraceptives and breast cancer: Do benefits outweigh the risks? A case–control study from Jordan. BMC Women’s Health, 19(1). https://doi.org/10.1186/s12905-019-0770-x
- Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An Updated Review. Cancers, 13(17), 4287. https://doi.org/10.3390/cancers13174287
Rubric Breakdown
| Criteria | Needs Improvement | Proficient | Distinguished |
| Risk Factor Identification | Fails to identify key risk factors (age, genetics, reproductive history). | Identifies common risk factors like family history and hormonal therapy. | Analyzes the interplay between complex factors like BRCA mutations and HRT. |
| Data Interpretation | Misinterprets the Gail Model percentages or U.S. averages. | Correctly identifies when a patient’s risk exceeds the national average. | Provides a nuanced comparison of 5-year vs. lifetime risks for each patient profile. |
| Clinical Recommendations | Suggests generic health advice with no clinical basis. | Recommends screenings (mammograms) and genetic testing (BRCA) based on data. | Proposes integrated care plans involving specific diets (DASH), specialists, and genetic counseling. |
| Pathophysiology Knowledge | Lacks understanding of how cancer spreads or genetic mutations work. | Explains basic concepts of metastasis (lymphatic spread) and genetic risk. | Demonstrates a deep understanding of hormone-receptor interactions and chemotherapy impacts. |
| Academic Writing | Numerous grammatical errors or improper APA citations. | Professional clinical tone with accurate APA 7th edition references. | Exceptional clarity and organization, using medical literature to justify every claim. |
Step-by-Step Guide
- Extract Bio-Data: List the age, reproductive history, and family cancer history for each patient.
- Run the Risk Tool: Compare the patient’s 5-year and lifetime risk percentages against the U.S. average.
- Identify Mary’s Focus: Connect her late menopause (58) and Estrogen therapy to her 12.1% lifetime risk.
- Identify Paula’s Focus: Highlight her metastatic bladder cancer and the need for BRCA1 testing.
- Identify June’s Focus: Address her “fragile bones” (osteoporosis) alongside her cancer risk.
- Identify Nora’s Focus: Note her exceptionally high lifetime risk (23.8%) due to early family history.
- Suggest Clinical Tests: Recommend specific tests like BRCA genetic screens, mammograms, or ultrasounds.
- Formulate Lifestyle Plans: Include diet (low alcohol, high soy/isoflavones) and physical activity.
- Synthesize Recommendations: Ensure the advice for one condition (like hypertension) doesn’t conflict with another.
- Final Proofing: Ensure the references from Łukasiewicz and others are properly formatted in APA.
Frequently Asked Questions
1. Why does late menopause increase breast cancer risk?
The longer a woman menstruates, the longer her breast tissue is exposed to estrogen and progesterone, which can stimulate the growth of some cancer cells.
2. What is the significance of the BRCA1 mutation?
BRCA1 is a tumor suppressor gene. When it mutates, the body can’t repair DNA damage effectively, making it much more likely that cancer (especially breast and ovarian) will develop.
3. Is “Bone Cancer” the same as “Breast Cancer”?
Note: In your profile, “bone cancer” is often used interchangeably with “breast cancer” due to translation or regional phrasing. In clinical assessments, ensure you are referring to Breast Cancer (malignancy of the mammary glands).
4. How does the DASH diet help a cancer patient?
While it primarily targets blood pressure, its focus on fruits, vegetables, and lean proteins helps reduce obesity and inflammation, both of which are environmental drivers of cancer growth.
Integrity Note
Note: Only use this assessment example for learning and structure purpose. Do not submit as your own work.
We are an independent resource and are not affiliated with Capella University.